TRANSMEDICS GROUP INC TMDX
ASignal's systematic analysis rates TMDX as Neutral.
Reflects the latest available analysis · analyzed Nov 10, 2026
The case on TMDX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (41.1% YoY)
- High gross margin (58.6%) indicating pricing power
- Exceptional ROE (31.89%) reflecting capital efficiency
- Positive free cash flow with solid operating cash flow ($112.36M)
- MACD histogram expanding above zero, signaling strengthening momentum
- RSI at 71.37, approaching overbought territory
- Price trading above upper Bollinger Band (87.32), suggesting premium valuation
- Forward P/E elevated at 37.73x despite high growth
- Earnings growth declining YoY (-29.8%) despite revenue growth
- Debt-to-equity ratio high at 1.57x, above ideal threshold
See the full verdict on TMDX
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes TMDX
Most investors never get a second opinion, let alone several. ASignal runs TMDX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.